US Stock MarketDetailed Quotes

LPCN Lipocine

Watchlist
  • 5.5400
  • +0.1200+2.21%
Close Oct 31 16:00 ET
  • 5.7955
  • +0.2555+4.61%
Post 20:01 ET
29.63MMarket Cap-3419P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

Comments

    $Lipocine (LPCN.US)$
    Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
    Lipocine Inc. (NASDAQ: LPCN) has entered into a license, development and supply agreement with SPC Korea for exclusive marketing rights of TLANDO® in South Korea. The agreement includes an upfront payment, potential regulatory and sales milestone payments, royalties on net commercial sales, and a supply price arrangement. SPC Korea will be responsible for obtaining...
    $Lipocine (LPCN.US)$ Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
    ● Quantitative Electroencephalogram (qEEG) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (NAS), confirmed GABAA modulation
    ● Rapid and durable CNS target engagement confirms effective oral delivery of bioidentical brexanolone
    ● Promising results support continued development of oral brexanolone for the treatment of neuropsychiatric disorders

    SALT LAKE CI...
    $Lipocine (LPCN.US)$
    Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
    Lipocine Inc. (NASDAQ: LPCN) has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO®, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries. The agreement covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
    Under the term...
    $Lipocine (LPCN.US)$ Reuters just
    Lipocine Announces Supply and Distribution Agreement With Pharmalink to Commercialize Tlando® in the Gulf Cooperation Council (GCC) Countries
    1
    $Lipocine (LPCN.US)$
    Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
    Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity
    SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 da...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data